A Caris & Co. analyst upgraded the stock of drug developer Alkermes Inc., pointing to the company's pending acquisition of a drug technology business.
A new lupus treatment developed by Human Genome Sciences Inc. is receiving a lukewarm reception from doctors so far, with demand for the drug shaping up to be much softer than expected, according to a Citi analyst.
The National Institutes of Health, in partnership with the Department of Defense, is building a central database on traumatic brain injuries.
Kuros Biosurgery completed patient recruitment in a clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.
Ipsen and Inspiration Biopharmaceuticals Inc. entered into a strategic partnership agreement, to create a European hemophilia commercial organization, to launch Inspiration’s hemophilia product portfolio in Europe.
The most common breast cancer uses the most efficient, powerful food delivery system known in human cells and blocking that system kills it, researchers report.
Collaborating researchers at Stanford University and The Scripps Research Institute have identified chemical compounds that show promise as potential therapeutics for a set of medical conditions caused by the abnormal clumping together of a protein known as transthyretin (TTR).
Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer -- mesothelioma, and melanoma of the eye.
Yale University researchers are looking to fight a form of cancer primarily found in children and young adults with a virus from the same family as the rabies virus.
Promega Corporation announced the launch of ONE-Glo + Tox Assay, for improved analysis of reporter gene expression in the context of cell health.
Highly modified, synthetic 5-prime capped mRNA products for reprogramming of human cells for reprogramming cell fate are now available from AMSBIO.
EMD Millipore, the Life Science division of Merck KGaA, announced it has agreed to acquire Seattle-based Amnis Corporation. Amnis designs, manufactures and markets high speed cell imaging instrumentation.
The drugmaker Perrigo Co. said the Food and Drug Administration has approved its generic version of the skin disease treatment Extina foam. Extina foam has annual sales of $10 million.
NuPathe Inc. said the Food and Drug Administration did not approve its Zelrix migraine patch. The FDA requested more information on the chemistry and manufacturing of the treatment, as well as citing safety concerns.
Teva Pharmaceutical Industries Ltd. said that its patent infringement lawsuit against companies that are trying to market a generic version of its multiple sclerosis drug Copaxone will go to trial.